COMPANY PROFILE

Definium Therapeutics

A psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness

New York City, United StatesFounded 2019Biotech & Life Sciences

Valuation $1.43B Market cap · 2026

About Definium Therapeutics

MindMed is a clinical stage biopharmaceutical company focused on developing novel product candidates to treat brain health disorders. The company aims to be a global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. MindMed operates in the biopharmaceutical market, targeting neurotransmitter pathways that play key roles in brain health disorders. The company's pipeline includes innovative drug candidates, both with and without acute perceptual effects, and digital therapeutics. MindMed serves patients suffering from various brain health disorders, leveraging its industry-leading drug development expertise to harness the therapeutic potential of psychedelics and other novel therapeutic targets. The business model revolves around advancing these drug candidates through clinical trials and eventually bringing them to market, generating revenue through the sale of these therapeutic solutions. The company is headquartered in New York, United States, and is committed to addressing the major unmet medical needs in brain health.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2019
Headquarters: New York City, United States
Listing: IPO 2020
Employees: 29
Open positions: 20
Dealroom signal: 62.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Mental Health, Verified Unicorns and $1B Exits, Tech for Biotech and Pharma, Post IPO $1B, Biotech and Pharma, Psychedelic Drugs, Addiction, DT and LS
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Feb 2021
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	Jun 2026	$805M	—	Undisclosed	↗
POST IPO EQUITYOther financing	Oct 2025	$259M	—	Evercore Partners · Leerink Partners	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	EBITDA	Margin
2026	−$155M	—
2025	−$155M	—
2024	−$92M	—
2023	−$84M	—
2022	−$74M	—
2021	−$94M	—
2020	−$33M	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Definium Therapeutics website traffic

Latest recorded traffic for Definium Therapeutics is 39K monthly website visits, up 116.7% over the last three months. Definium Therapeutics's team declined 77.7% over the past year.

Latest monthly visits39K 3-month web change+116.7% 1-year team growth-77.7%

Monthly website visitsMar 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Associate Director, Medical WritingDurham, North Carolina, United States · Other · Jan 22, 2026 Senior R&D System AdministratorDurham, North Carolina, United States · Backend Development · Jan 16, 2026 Associate Director, Statistical ProgrammingDurham, North Carolina, United States · Accounting · Jan 16, 2026

3 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ASATAI Life SciencesA biotechnology company pioneering mental health innovation	Berlin, Germany	Acquired	106	$387M	$2.5B
CPCOMPASS PathwaysPsilocybin-based therapies for treatment-resistant mental health conditions	London, United Kingdom	Operational
UIUniversal IbogaineTransform addiction recovery with the healing power of Ibogaine	Vancouver, Canada	Operational
SESepternaBiotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs)	San Francisco, United States	Operational
SPSupernus PharmaceuticalsSpecialty pharmaceutical firm commercializing central nervous system treatments	Rockville, United States	Operational
KTKaruna TherapeuticsClinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions	Boston, United States	Acquired
DTDiamond TherapeuticsDeveloping accessible, low-dose therapies for mental health conditions	Toronto, Canada	Operational
BBBright Minds BiosciencesBiotechnology company creating the next generation of psychedelics to treat mental health and other CNS disorders	New York City, United States	Operational